ID   OMM-1
AC   CVCL_6939
SY   OMM1; Omm1
DR   cancercelllines; CVCL_6939
DR   Cosmic; 848331
DR   Cosmic; 899895
DR   Cosmic; 916147
DR   Cosmic; 1628402
DR   Cosmic; 1669126
DR   Cosmic; 2036704
DR   DepMap; ACH-002017
DR   Wikidata; Q54936368
RX   PubMed=8621261;
RX   PubMed=16772116;
RX   PubMed=22236444;
RX   PubMed=23849826;
RX   PubMed=24994677;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 34 hours (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=22236444; PubMed=24994677).
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): DepMap; PubMed=22236444; PubMed=24994677
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12 (PubMed=22236444)
ST   D13S317: 12 (DepMap; PubMed=24994677)
ST   D16S539: 9
ST   D18S51: 13,14
ST   D21S11: 30,30.2
ST   D3S1358: 14,17
ST   D5S818: 11
ST   D7S820: 13
ST   D8S1179: 10,16
ST   FGA: 20
ST   Penta D: 9,12
ST   Penta E: 5,7
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 19
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=8621261; DOI=10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F;
RA   Luyten G.P.M., Naus N.C., Mooy C.M., Hagemeijer A., Kan-Mitchell J.,
RA   van Drunen E., Vuzevski V., de Jong P.T.V.M., Luider T.M.;
RT   "Establishment and characterization of primary and metastatic uveal
RT   melanoma cell lines.";
RL   Int. J. Cancer 66:380-387(1996).
//
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by Gefitinib and Cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//